Amphastar Pharmaceuticals (AMPH) Competitors

Amphastar Pharmaceuticals (NASDAQ:AMPH) and Protagonist Therapeutics (NASDAQ:PTGX) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, media sentiment, profitability, dividends, community ranking, earnings, risk and institutional ownership.

Which has more volatility and risk, AMPH or PTGX?

Amphastar Pharmaceuticals has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of 2.17, meaning that its share price is 117% more volatile than the S&P 500.

Do analysts prefer AMPH or PTGX?

Amphastar Pharmaceuticals currently has a consensus target price of $63.00, suggesting a potential upside of 32.44%. Protagonist Therapeutics has a consensus target price of $49.86, suggesting a potential upside of 10.60%. Given Amphastar Pharmaceuticals' higher probable upside, equities research analysts plainly believe Amphastar Pharmaceuticals is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amphastar Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Protagonist Therapeutics	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.14

Does the media prefer AMPH or PTGX?

In the previous week, Amphastar Pharmaceuticals and Amphastar Pharmaceuticals both had 7 articles in the media. Protagonist Therapeutics' average media sentiment score of 1.63 beat Amphastar Pharmaceuticals' score of 0.81 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amphastar Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Protagonist Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Which has preferable earnings & valuation, AMPH or PTGX?

Amphastar Pharmaceuticals has higher revenue and earnings than Protagonist Therapeutics. Amphastar Pharmaceuticals is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amphastar Pharmaceuticals	$712.89M	3.26	$137.54M	$2.89	16.46
Protagonist Therapeutics	$60M	44.25	-$78.96M	$2.62	17.21

Does the MarketBeat Community favor AMPH or PTGX?

Amphastar Pharmaceuticals received 119 more outperform votes than Protagonist Therapeutics when rated by MarketBeat users. Likewise, 66.38% of users gave Amphastar Pharmaceuticals an outperform vote while only 60.71% of users gave Protagonist Therapeutics an outperform vote.

Company	Underperform	Outperform
Amphastar Pharmaceuticals	Outperform Votes 391 66.38%	Underperform Votes 198 33.62%
Protagonist Therapeutics	Outperform Votes 272 60.71%	Underperform Votes 176 39.29%

Is AMPH or PTGX more profitable?

Amphastar Pharmaceuticals has a net margin of 23.36% compared to Protagonist Therapeutics' net margin of 0.00%. Protagonist Therapeutics' return on equity of 39.06% beat Amphastar Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amphastar Pharmaceuticals	23.36%	29.79%	12.75%
Protagonist Therapeutics	N/A	39.06%	35.19%

Do insiders & institutionals have more ownership in AMPH or PTGX?

65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are held by institutional investors. 27.1% of Amphastar Pharmaceuticals shares are held by company insiders. Comparatively, 5.4% of Protagonist Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Protagonist Therapeutics beats Amphastar Pharmaceuticals on 10 of the 18 factors compared between the two stocks.